Providing a once-daily extended release dosage of levorphanol, LevoCap is intended to treat chronic pain and potentially reverse a patient’s analgesic tolerance to morphine.
Relmada anticipates launching a Phase 3 study for the drug in 2013, according to CEO Sergio Traversa.
Related Articles on Pain Management:
Middle Fork Surgery Center Visited by Oregon’s Co-Speaker of the House
Dr. Daniel Carr Named PAINWeek 2012 Keynote Speaker
Neurostimulation Field Draw Investor Attention
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
